Shire PLC (SHPG) Shares Sold by Ashfield Capital Partners LLC
Ashfield Capital Partners LLC reduced its position in Shire PLC (NASDAQ:SHPG) by 13.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,318 shares of the biopharmaceutical company’s stock after selling 2,525 shares during the period. Ashfield Capital Partners LLC’s holdings in Shire PLC were worth $2,499,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SHPG. Hartford Financial Management Inc. lifted its stake in shares of Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares in the last quarter. YorkBridge Wealth Partners LLC lifted its stake in shares of Shire PLC by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 317 shares in the last quarter. Pacer Advisors Inc. acquired a new position in shares of Shire PLC in the 2nd quarter valued at about $171,000. Stephens Inc. AR lifted its stake in shares of Shire PLC by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 228 shares in the last quarter. Finally, Ingalls & Snyder LLC lifted its stake in shares of Shire PLC by 10.8% in the 2nd quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 125 shares in the last quarter. 18.27% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have recently weighed in on SHPG shares. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Piper Jaffray Companies set a $159.00 target price on Shire PLC and gave the company a “hold” rating in a report on Wednesday, July 26th. Royal Bank Of Canada set a $213.00 target price on Shire PLC and gave the company a “buy” rating in a report on Friday, August 4th. Zacks Investment Research upgraded Shire PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $206.00 target price (down from $216.00) on shares of Shire PLC in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. Shire PLC has an average rating of “Buy” and a consensus price target of $212.18.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/16/shire-plc-shpg-shares-sold-by-ashfield-capital-partners-llc.html.
Shire PLC (SHPG) traded up $0.76 during mid-day trading on Thursday, reaching $140.03. The company’s stock had a trading volume of 825,300 shares, compared to its average volume of 1,133,322. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire PLC has a 52 week low of $137.17 and a 52 week high of $192.15. The stock has a market cap of $41,840.47, a P/E ratio of 9.58, a PEG ratio of 0.77 and a beta of 1.60.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.64 by $0.17. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The company had revenue of $3.70 billion for the quarter. During the same quarter in the prior year, the firm earned $3.17 earnings per share. Shire PLC’s revenue for the quarter was up 7.1% compared to the same quarter last year. equities research analysts anticipate that Shire PLC will post 15 EPS for the current fiscal year.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.